Legal Entity
Insights
CARMINE THERAPEUTICS PTE. LTD.
Last Updated: 17 Jun 2026
Carmine Therapeutics is a biotechnology company pioneering a novel class of non-viral gene therapies using red blood cell extracellular vesicles (RCEVs) combined with proprietary payloads. Our mission is to revolutionize the treatment of genetic diseases through innovative, safe, and effective therapies. In June 2020, we formed a strategic alliance with Takeda Pharmaceuticals valued at up to $900 million to develop non-viral gene therapies for two target indications. We have been recognized as one of FierceBiotech's Fierce 15 Biotech companies of 2020 and received the Bristol-Myers Squibb 'Golden Ticket'. With a strong scientific advisory board led by Professor Harvey Lodish, a founding member of multiple successful biotech companies, we are committed to advancing our pipeline of RCEV-based therapies and improving the lives of patients worldwide.
Country of registration | Singapore |
Registration number | 201900572Z |
Local SIC | |
Incorporation date | 4 Jan 2019 |
Company age | 7 years 5 months |
Official entity type | Private Limited Company |
No. of officers | 4 |
Contact
Address:
19 CHANGI SOUTH STREET 1, Singapore 486779
Access Key Decision Makers
This is the legal entity page of CARMINE THERAPEUTICS PTE. LTD.. To access company info, company size, news , key makers’ emails, visit the profile pages above.
Associated business (1)
- View MoreCarmine Therapeutics is a biotechnology company pioneering a novel class of non-viral gene therapies using red blood cell extracellular vesicles (RCEVs) combined with proprietary payloads. Our mission is to revolutionize the treatment of genetic diseases through innovative, safe, and effective therapies. In June 2020, we formed a strategic alliance with Takeda Pharmaceuticals valued at up to $900 million to develop non-viral gene therapies for two target indications. We have been recognized as one of FierceBiotech's Fierce 15 Biotech companies of 2020 and received the Bristol-Myers Squibb 'Golden Ticket'. With a strong scientific advisory board led by Professor Harvey Lodish, a founding member of multiple successful biotech companies, we are committed to advancing our pipeline of RCEV-based therapies and improving the lives of patients worldwide.
This is the legal entity page of CARMINE THERAPEUTICS PTE. LTD.. To access company info, company size, news, key maker's emails, visit the profile pages above.
Financials
Fiscal/Budgeting Period | October - December |
Revenue | 6m - 10m |
Financial period end date | 31 Dec 2020 |
Share Capital - Ordinary shares | SGD 1 |
Last updated: 17 Jun 2026
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Discover More Companies
Lookalike companies
* This profile contains information from ACRA Information on Corporate Entities from Accounting and Corporate Regulatory Authority which is made available under the terms of the Singapore Open Data Licence version 1.0. Information and datasets on our website are provided on an “as is” and “as available” basis. This website makes no representations or warranties concerning the datasets, including but not limited to any representation or warranty as to the accuracy, completeness, reliability, continued availability, timeliness, non-infringement, title, quality, or fitness for any particular purpose of the datasets to the fullest extent permitted by the law.
Frequently Asked Questions (FAQ)
- What is the address of CARMINE THERAPEUTICS PTE. LTD.?
- Where is CARMINE THERAPEUTICS PTE. LTD.'s headquarter?
- What is CARMINE THERAPEUTICS PTE. LTD.'s contact number?
- What CARMINE THERAPEUTICS PTE. LTD.'s spending power?
- Does CARMINE THERAPEUTICS PTE. LTD. have a presence in the domain it operates in?